{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-036224","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.890551+00:00","generated_at":"2026-06-06T02:08:26.125246+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"KalVista terminates $100M ATM sales agreement with Cantor Fitzgerald; no shares sold","bullets":["Terminated Controlled Equity Offering Sales Agreement with Cantor, effective Feb 14, 2024.","Agreement allowed up to $100M in common stock sales; company sold zero shares under it.","Cantor waived notice period, making termination immediate upon close of business Feb 14.","Termination has no effect on operations or capital; company retains other financing avenues."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-036224","json":"https://secwatch.observer/filing/0001193125-24-036224.json","markdown":"https://secwatch.observer/filing/0001193125-24-036224.md","text":"https://secwatch.observer/filing/0001193125-24-036224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/0001193125-24-036224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/d771919d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:08:26.125246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13bb1efaa487ae6d5e936c1653be1b6b9734777c","claim":"KalVista Pharmaceuticals, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at no shares sold under the agreement; aggregate offering price up to $100.0 million (effective 2024-02-14).","evidence_excerpt":"On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) delivered a written notice of termination (the “Termination Notice”) of that certain Controlled Equity Offering Sales Agreement (the “Sales Agreement”), dated May 21, 2021, by and between the Company and Cantor Fitzgerald & Co., as sales agent (“Cantor”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/0001193125-24-036224-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"no shares sold under the agreement; aggregate offering price up to $100.0 million"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}